cated because it has to do with the whole economy and social security as well. We have done some scenarios for 2040, look ing at the older population, and one of those scenarios that's very interesting sees an older, healthier society that is more productive in its older years. Therefore you do tend to see a rising age of retire ment, which is a reversal of the current trend. Another scenario has productivity increasing so much from automated sys tems, that in effect we have to, as a soci ety, divorce work from income, so that there would be some kind of guaranteed income. In this scenario you see some people working on past the age of retire ment and other people retiring at very ear ly ages because much of the work is per formed by machines.
Cooley: Mr Peck, you mentioned the third world. We know that there are dis eases and disorders that are rampant in the third world, and many of these can be treated effectively by OTCs. What do you see about their future, economic status, the demand for OTCs? In fact, what is the market in the third world?
Peck: It's a pretty hard one to aggregate because delivery systems are so problem atic there that the distinction between Rx and OTC breaks down in many countries outside our own. I guess the main thing I see is that current trends can't continue; that it reaches a point where-if you pro-ject a trend out like Dr Schondelmeyer's growth of percentage of GNP, at some point it becomes a "no-brainer," a projec tion you can't sustain, like getting up to 100% of GNP. I don't think we can sus tain the differences between the first world and the third world, particularly with the growing population there and the shrink ing population in the developed world.
Cooley: Dr. Schondelmeyer, regarding not just the third world, but countries in gen eral, would you say that there's a group of countries that now have the most econom ically "valid," if we may say, healthcare system? And which countries are those?
Schondelmeyer:
That's a difficult judg ment to make. I would say that there is a great deal of interest among health policy makers in some of the Scandinavian coun tries, and in Canada, as examples of sys tems to look at. There are none that I think are worthy of complete patterning after with respect to the US healthcare sys tem. We have a great healthcare system in the United States. I would hate to see it dismantled or disrupted in a major way, but I think also we are going to go through pressures to level off the growth rate in expenditures. So the US healthcare system has a choice of "learn to live with" a lev eled off growth rate in a stable economic market, or have imposed upon it by gov ernment or others demands some way of controlling costs that it didn't choose. So US healthcare has a choice. Can this in dustry and healthcare, including pharma ceuticals, physicians, hospitals, and oth ers, learn to manage their growth rate and work with a stable percentage of the econ omy, or are they going to leave it up to somebody else to help them make those decisions?
Cooley: Mr Peck, biofeedback is a more important part of drug dosing decisions. Now, in view of that, and the need in the informational portion on OTC products, do you see that's going to force the FDA to redefine what's a device and what's a drug? Where do the categories lie?
Peck: The lines are blurring and the cate gories become less useful throughout the FDA, and it's not only devices and drugs; it's drugs and foods. So I think it's going to be increasingly difficult and it will de mand flexibility on the part of the Agen cy. I'm sort of confident that they'll be able to be flexible, particularly if given the resources and the information systems to enhance that.
Mr Jerome Halperin: Mr Peck, would you stare at your crystal ball a little more spe cifically and give us an example of this Rx-to-OTC switch product in the future that will have the information technology embedded in it. What's it going to look like? What's it going to do? Who's going to use it? Peck: That's a great question. I would see one being, for example the kind of pack aging for "the pill" that helps a consumer by giving them a compliance aid. Well, I think they'll be far more sophisticated. There will be enough chips embedded in packaging, for example, that for a con sumer to even get the medication, he has to demonstrate a knowledge in terms of how it's going to be used, so that it ensures that the use is a safe one. So I would see increasingly sophisticated packaging sys tems that have dispensing tied to knowl edgeable use.
Cooley: Dr Schondelmeyer, you are an expert on the Catastrophic Care Law. What's wrong with it as it stands today, and what can fix it? Schondelmeyer: I think it's inappropriate to describe what's wrong with something before we try it out. Certainly, there are things that have many people concerned: there are those who are saying it's going to cost too much; can they ever accomplish the technology that's required in the Act?
Can we afford to pay for the program? Yet, on the other side, we're beginning to see that the revenues may be coming in a little faster than we expected, and we don't see a lot about that in the press. Second, we hear that the elderly are very upset with the law. What we hear them saying, though, is: I don't want to pay the full cost of it. Very few are saying, "I don't want a drug benefit." They're just saying, "I don't want to pay the full cost. Let's spread around the cost." From the elderly's point of view, they see that they're pay ing a very high catastrophic cost up front for catastrophic coverage later on. From the industry standpoint and the pharma cist's standpoint, there are concerns about the workload, the changes in the way the reimbursement structure will operate; and whether this act will affect their profit ability significantly. Will this limit the amount that a pharmacist makes to the point that there's little or no profit in it for the pharmacist-that essentially we drive most community pharmacy settings out of practice? Will it affect manufacturers and their pricing of generic and brand name products to the point that they cannot af ford the investment in innovation and re search and development? All of these are macro concerns that we need to be, as a society, very aware of as we go into a pro gram of this magnitude. We have to begin a program, though, and do some tinkering as we begin moving, rather than go in with a negative attitude like "It can't ever work."
Cooley: Mr Peck, you talked about manu facturers being in the information busi ness more and more in the future. Do you have any comments on the wholesalers or the retailing part of the business as being in the information business?
Peck: Yes, I think that's absolutely a trend that we're going to see. It's already emerged somewhat in groceries, where there are automated systems at the cash registers, and they're picking up real time marketing information that they are now beginning to sell. So I think that retail in formation with intermediaries already has proven to be a very valuable commodity, and I suspect that retailers will start to want to play in that particularly as they get more sophisticated tools for collecting and analyzing.
Cooley: Does either of you see OTC drugs as coming under third-party payment schemes in the future, and what would bring that about?
Peck: In the short term, probably not. They're in effect emphasizing the Rx side. But then in the long term, I would say yes. I would see it particularly if we're talking about embedded information systems. There's an argument that in effect OTCs can pay for themselves by reducing other healthcare bills, and managed healthcare systems have tremendous incentives to make those reductions. I think we will start to see that marriage of information and product that can provide cheaper and more effective self-care and that institu tional players will want to pay for it.
Schondelmeyer: I didn't comment on that earlier but I had intended to. I do agree. I think we'll see OTCs covered by third par ty programs. The more mature HMOs and managed healthcare systems even today are covering certain nonprescription medi cations as substitutes for prescription medications when they have equal effec tiveness, equal safety and less cost. What I don't think we'll see is OTCs covered for just pure convenience, symptomatic thera py. I think we'll see them when they are truly effective at maintaining major symp toms that would lead to further adverse consequences . . . then we'll see those OTC products; things like the use of aspi rin for arthritis and other medications of that type will increasingly be covered un der third party programs. But we have to learn to control such use so it does not become an "all the drugs you want to use under the plan" type OTC coverage. Rath er, OTC coverage should be offered under terms that say "Here's a defined legitimate need, and here's a way we can provide you less costly, equally effective, equally safe medication."
Cooley: Mr Peck, how do you know whether the changing value systems will continue to encourage growing numbers of people to ask for more self-care prod ucts, including the OTC drugs? How do you know that?
Peck: You don't. One of the things is you look at historical data and you start to try to tease out why these things are coming about. You look at large changes that are societal-wide. I think at times of econom ic downturn, you may see some value shifts going in the other way. A stressed society does have different values. We saw that in the depression, for example. Fertil ity took a big drop. I mean, people's be haviors and values are affected by exter nals. But nonetheless, the overall pattern of change has been that if you look at these developed world markets -I've talked about Japan, the United States, and Europe-very different cultures, com ing out of very different experiences. The book, A Triad Power, suggests a pattern of buying, of consumptions of value-ori entation that I've also viewed personally, that says these worlds are all changing this way. This pattern is real.
Cooley:
The last question, this will be for Dr Schondelmeyer: "Can a company earn more with a drug that's gone OTC ν the same drug as Rx? And please consider overhead costs for the Rx, detailing, ad vertising costs for the OTC." Schondelmeyer: That's a very difficult question. The same product taken OTC by different companies would have different answers. We have different companies that have different capabilities and differ ent abilities to market and achieve the po tential of a product in the marketplace. First of all, I do think that in many cases, if you have a product that's truly effective, and has a good safety record, that you probably will have more total revenue po tential if you include the self-care market or the OTC market, rather than the Rx only availability, as soon as is possible. But I have to qualify that-that the drug is safe, effective, and is a significant thera peutic advance. If you've really got some thing worth marketing, you could proba bly make more with it as an OTC. But there are so many decisions that a compa ny has to make in that Rx-to-OTC switch process. Most all products we're going to see will come in as Rx first and will be there for some period of time before they go OTC. It would be rare if not impossible today to go direct to the OTC market with a new chemical entity. I do think that companies have to realize that marketing in the OTC market has a totally different promotional emphasis and promotional strategy. In fact, your best choice may not be to market the OTC product yourself, but to contract with someone else, some body like a Procter & Gamble that knows the consumer market. In the example of Advil, Boots went to American Home Products, and they did an excellent job of marketing that product on a licensing ba sis. We've seen Merck and Johnson & Johnson Group form a coalition where Merck is going to allow their Rx-to-OTC switched products to be licensed and marketed through the McNeil Consumer Products Group. We'll see more and more companies with good Rx products that want to test out the potential or consider what can be done with them on the OTC side. These companies should go with those with the expertise on the OTC side. Just because you can market an Rx prod uct well doesn't mean that you're going to be a success at marketing an OTC prod uct. You have to consider: Are you going to have a dual product -both an Rx and an OTC? Are you only going to go one way or the other? Are you going to canni balize your Rx market? There are many factors, and I can refer you to some stud ies and writings on those effects that need to be considered. In general one could probably market a product and do better on the OTC side in the long run, if it meets the safety and effectiveness criteria.
